Study at a glance
What happens to vitamin D blood levels after one large dose?
This controlled trial followed 40 healthy adults for four months. Thirty took one dose of 100,000 international units (IU) of vitamin D3 by mouth. Ten did not receive it and provided a comparison for seasonal changes. Participants had limited sun exposure and low milk intake. People with certain illnesses or taking medicines that affect vitamin D were excluded. The dose describes the experiment, not a recommendation.
How much did vitamin D blood levels rise after the dose?
Researchers measured 25-hydroxyvitamin D, the form measured in the usual vitamin D blood test. In the group given vitamin D, the average rose from 27.1 ng/mL to a highest average of 42.0 ng/mL, then fell. The comparison group had only a small change that could have been due to chance. This supported the conclusion that the dose caused the rise.
Did everyone reach the same vitamin D blood level?
No. The highest individual result was 64.2 ng/mL. About 7% of the supplemented group never reached 32.1 ng/mL, the boundary used in this study. These are measured results and a study boundary, not personal blood-level targets. The study could not explain whether differences came from absorption, storage, conversion or removal of vitamin D.
Does one large vitamin D dose establish health benefits or long-term safety?
This small study measured changes in blood levels, not health benefits or vitamin D activity inside tissues. Its selected healthy participants may not represent other groups. One large dose does not establish the effects or long-term safety of daily doses or repeated large doses.
Read the full article below ↓This page presents the full evidence record for this study. A concise overview is available on the Study Summary page.
Evidence from a single verified scientific study evaluated using a fixed, auditable study-page structure.
Study classification and identity
Study type
Randomized controlled trial (supplemented group vs contemporaneous control group)
Parent study or cohort
Not applicable
Ancillary analysis focus
Not applicable
Exposure type
Single oral dose of cholecalciferol (vitamin D3), 100,000 IU
Comparison or grouping structure
Supplemented group (n=30) vs control group (n=10) to characterise seasonal change in calcidiol
Primary endpoint category
Biochemical marker kinetics (serum 25-hydroxyvitamin D / calcidiol time course)
Clinical endpoints assessed
None (safety/physiologic monitoring referenced via calcium in study framing; no clinical outcomes)
Study purpose and framing
This study is framed around a practical physiological question: what happens, over time, to the circulating vitamin D status marker after a single large oral dose of cholecalciferol. The authors explicitly situate the work in the context of intermittent dosing, where the goal is convenience and adherence rather than daily intake, and the evidentiary object becomes the time course of serum calcidiol (25-hydroxyvitamin D) following a bolus exposure. The research intent is therefore kinetic and descriptive: to characterise the rise, peak, and persistence of the marker response over months after one defined exposure, within a population chosen to minimise untracked vitamin D inputs from sunlight and diet.
Outcomes are framed narrowly as changes in serum calcidiol concentration over a four-month follow-up, with an explicit comparator group used to estimate background seasonal drift over the same period. The study does not frame its outcomes as tissue-level distribution across multiple organs; instead, it treats serum calcidiol as the system-level readout of whole-body handling of cholecalciferol exposure (absorption, conversion, and clearance) without direct measurement of each step. The boundary of inference is therefore constrained to what serum calcidiol can represent: a downstream circulating metabolite response to a known dose, not a direct assay of tissue stores, intracellular signalling, or endpoint physiology.
The study explicitly does not attempt to resolve long-term clinical benefit, disease risk modification, or comparative effectiveness across different dosing regimens beyond the bolus pattern tested. It also does not attempt to resolve mechanistic questions such as which tissues dominate conversion at various time points, what fraction of the dose is stored in specific depots, or how binding-protein dynamics alter delivery. The trial is structured to answer a single operational question: given one 100,000 IU exposure, what is the observed serum calcidiol trajectory over four months in the selected participant context, and how variable is that trajectory across individuals.
Why the primary measure is used as a biological marker
Serum 25-hydroxyvitamin D (calcidiol) is used here as the primary marker because it is the predominant circulating vitamin D metabolite routinely used to represent “vitamin D status” in human studies, and because it integrates multiple upstream processes into a single measurable output. In the context of a bolus cholecalciferol exposure, calcidiol behaves as a delayed and smoothed readout: it reflects intestinal absorption of cholecalciferol, subsequent conversion to 25-hydroxyvitamin D, and the balance of clearance and distribution. The study’s objective is explicitly kinetic; a marker that can be repeatedly measured over months with acceptable stability is therefore central to the design.
Using calcidiol as the primary readout imposes interpretive guardrails. The marker is not a direct measure of total body vitamin D content, tissue-specific exposure, receptor activation, or intracrine/paracrine signalling intensity. The study can describe how a defined bolus changes circulating calcidiol over time, and it can show whether some individuals fail to reach specified concentrations, but it cannot claim where the dose resides in the body, which tissues are functionally replete, or whether downstream vitamin D signalling pathways are engaged to any particular degree. Any inference beyond “serum calcidiol concentration changed in this pattern” would exceed what the design measures.
Measurement context also constrains interpretation because calcidiol is sensitive to baseline status, recent inputs, seasonality, and inter-individual differences in metabolism and distribution. The trial attempts to reduce uncontrolled inputs by selecting participants with limited sun exposure and low milk consumption, and by using a control group to quantify seasonal change. Even with these constraints, variability remains: a large bolus can yield different peaks and different persistence profiles across people, and a serum marker cannot distinguish whether that variability is driven by absorption, storage, conversion efficiency, distribution volume, or clearance differences.
General physiological context (not derived from this study): circulating calcidiol is commonly treated as a system-level indicator because it has a longer half-life than the active hormone (1,25-dihydroxyvitamin D) and because it rises and falls with changes in vitamin D inputs across days to weeks. In physiology-first terms, calcidiol is best understood as a circulating reservoir-like metabolite whose concentration is shaped by input, conversion, distribution, and elimination, but it is not itself a direct proxy for tissue-level signalling outcomes, which can be locally regulated and decoupled from serum concentration in some contexts.
Study overview
The study population consists of healthy adults selected to minimise confounding from untracked vitamin D inputs and from conditions known to alter vitamin D metabolism. Participants had limited sun exposure (reported as less than 10 hours per week) and low milk consumption (reported as less than 0.47 L daily). The follow-up period was four months, chosen to observe both the early response to a single large oral dose and the subsequent decline toward baseline as the exposure dissipates through conversion, distribution, and clearance processes as represented by serum calcidiol.
The exposure distribution is binary by design: a supplemented group received a single oral bolus of 100,000 IU cholecalciferol, while a control group did not receive the bolus and served specifically to quantify seasonal change in calcidiol over the same time period. This comparator structure is not intended to test clinical outcomes; it exists to support interpretation of the time course by separating bolus-driven change from background drift that might occur even without supplementation during the relevant months.
Key operational definitions are centred on serum calcidiol concentration and its kinetic descriptors over time: baseline concentration, post-dose rise, maximum achieved concentration, failure to achieve a defined threshold at any measured time point, and the control group’s change over the same duration. The study treats the bolus dose as a single discrete input and the serial serum calcidiol measurements as the observable output of the system. It also defines exclusions to avoid metabolic states and medications that could materially alter vitamin D handling.
Study design and measurement approach
The design is a randomized controlled trial structure in which one cohort receives the bolus exposure and another acts as a control for seasonal change. The recruitment strategy is not presented here as a population-representative sampling frame; instead it is a physiology-focused selection intended to support a clean kinetic readout. Exclusion criteria were used to remove participants with granulomatous conditions, liver disease, kidney disease, or diabetes, and to exclude those taking medications (anticonvulsants, barbiturates, steroids) that could alter vitamin D metabolism, binding, or clearance pathways. This design choice prioritises interpretability of the biomarker time course over generalisability to clinical populations.
The principal measurement instrument is repeated serum calcidiol concentration assessment across the follow-up period. The study describes serum calcidiol concentrations being followed for four months after dosing, implying multiple time points that capture both early rise and longer decay. The PubMed record also references radioimmunoassay within indexing terms, consistent with the common clinical-laboratory approach for calcidiol measurement during the time period. The study’s evidentiary object is therefore not a tissue assay or mechanistic cellular readout but a repeated circulating biomarker measurement series.
Timing and cadence are central because kinetics are the outcome. The study design requires that sampling extends long enough to detect peak concentration and subsequent decline, and that it is frequent enough early after dosing to observe the “prompt” rise described by the authors. While the PubMed summary does not enumerate each sampling day, the four-month window is explicitly stated, and the interpretation hinges on the relationship between a single dose and sustained serum calcidiol elevation relative to baseline and to controls.
Methodological trade-offs are visible in the study’s structure. By choosing serum calcidiol as the sole primary marker, the study gains feasibility and repeatability but loses direct visibility into tissue uptake and storage, binding dynamics, and local activation. By selecting a healthy cohort with exclusions, the study tightens physiologic interpretability but limits transferability to populations where dosing convenience might be most clinically relevant. By using a contemporaneous control group for seasonality, the study strengthens attribution of change to the bolus, but it still cannot fully partition the sources of inter-individual variability in response magnitude and persistence.
Outcome hierarchy
Directly measured outcomes
Serial serum 25-hydroxyvitamin D (calcidiol) concentrations over 4 months; baseline-to-peak change; maximum achieved concentration; proportion not achieving a defined concentration threshold; change in controls over the same period
Outcomes explicitly not measured
Tissue concentrations of cholecalciferol or metabolites; binding protein fractions (free vs bound); 1,25-dihydroxyvitamin D kinetics; receptor activation; clinical endpoints
Outcomes not inferable from this study
Whole-body vitamin D distribution across specific organs; intracrine/paracrine signalling magnitude in tissues; disease risk modification; long-term safety beyond the measured follow-up context
Statistical analysis
The analytical framework is oriented around describing and comparing biomarker trajectories rather than modelling clinical outcomes. The supplemented group’s serum calcidiol values are summarised as baseline mean and standard deviation, peak (maximum) mean and standard deviation, and extremes (highest achieved concentration). The control group’s change over four months is summarised as mean change with variability and characterised as non-significant. The statistical emphasis therefore appears to be on quantifying magnitude of response and distinguishing bolus-driven change from background variation.
Covariate strategy is primarily handled through design rather than complex adjustment: the trial restricts sun exposure and milk intake, and uses explicit exclusion criteria for conditions and medications known to affect metabolism. This approach reduces, but does not eliminate, residual variability. The study also highlights that a minority failed to reach a stated concentration at any time point, signalling that inter-individual differences remain even under controlled selection; however, the PubMed record does not specify multivariable modelling to explain those differences.
Handling of missing data and sensitivity checks are not described in the PubMed summary. The control group’s role functions as a built-in sensitivity check for seasonal drift: if serum calcidiol changes materially over the same period without bolus exposure, attribution of the supplemented group’s change would be weakened. Instead, the control group change is described as non-significant and small in magnitude, supporting the interpretation that the supplemented group’s rise is attributable to the intervention rather than to season.
Effect size interpretation in this study is fundamentally descriptive. The reported rise from baseline to peak provides a direct magnitude of change in ng/mL, while the reported maximum achieved concentration and the proportion failing to cross a threshold contextualise response heterogeneity. These outputs do not imply tissue-level sufficiency, functional outcomes, or clinical benefit; they imply that a single defined bolus is associated with a measurable and time-limited elevation of serum calcidiol in the selected population, with non-trivial variability across individuals.
Results
The primary reported finding is a prompt rise in serum calcidiol after a single 100,000 IU oral cholecalciferol dose. The supplemented cohort’s mean baseline calcidiol concentration is reported as 27.1 ± 7.7 ng/mL, rising to a reported maximum mean concentration of 42.0 ± 9.1 ng/mL. This establishes both the direction (increase) and magnitude (approximately +15 ng/mL at the level of group means) of the serum marker response to the bolus, within the follow-up window. The time course is described as being followed for four months, meaning the rise is not treated as a transient spike but as a trajectory with persistence and decline that can be observed over months.
A key secondary result is heterogeneity of response, operationalised in two ways. First, 7% of the supplemented cohort failed to achieve 32.1 ng/mL at any measured time point, indicating that even with a large bolus, some individuals did not reach that specified concentration threshold during the observation period. Second, the highest achieved concentration observed in any subject was 64.2 ng/mL, demonstrating that peak concentrations can vary substantially beyond the group mean peak. Together, these observations show that the same discrete dose can yield materially different serum calcidiol maxima and threshold attainment patterns across individuals.
The control group results function as a null comparator for seasonal drift: the control group had a mean change from baseline of -0.72 ± 0.80 ng/mL over four months, described as non-significant. This supports the inference that the supplemented group’s increase is unlikely to be explained by background seasonal movement in calcidiol during the study period. Importantly, this control result is not used to claim causal clinical benefit; it is used to stabilise attribution of biomarker change to the bolus exposure rather than to uncontrolled environmental change.
The authors’ results-linked caveat is embedded in their dosing-interval conclusion: they state that the dosing interval should be less than or equal to two months to ensure continuous serum calcidiol concentrations above baseline. This is an interpretive statement derived from the observed trajectory over four months: if calcidiol declines back toward baseline within that timeframe, then a longer interval risks periods where serum levels return to pre-dose state. This inference remains within the marker domain; it does not claim that being “above baseline” maps to a specific physiologic outcome, only that the marker does not remain elevated indefinitely after a single bolus even at 100,000 IU.
Measurement considerations and limitations
The core measurement limitation is that serum calcidiol is a proxy marker, not a direct measure of tissue distribution, storage, or signalling. A bolus can be absorbed, distributed into compartments, stored in depots, converted to metabolites, and cleared, but this study observes only the net effect of those processes on circulating calcidiol. Therefore, the study cannot specify which physiological step dominates the time course, nor can it distinguish whether a low responder failed due to absorption differences, distribution volume, storage dynamics, conversion efficiency, or clearance rate. The marker is informative about system-level output but non-specific about underlying mechanisms.
Representativeness is limited by design. Participants are healthy and selected to have limited sun exposure and low milk consumption, and the study excludes several conditions and medication classes. These constraints improve interpretability of kinetics in a cleaner physiological setting but reduce direct transferability to populations with chronic disease, altered metabolism, or higher baseline inputs. In addition, the study is designed around a single large bolus; it does not provide direct evidence about daily dosing kinetics, nor about repeated-bolus steady-state patterns beyond the inference the authors draw from the observed decline.
Because the trial uses an intervention design, classic observational confounding and reverse causality are not the main threats to the primary inference that the bolus increased calcidiol relative to control. However, residual sources of variability still matter: unmeasured differences in baseline status drivers, adherence to sun/diet constraints, and biological heterogeneity in metabolism could influence response magnitude. The control group helps address seasonal drift, but it does not explain individual response dispersion within the supplemented group. The study therefore describes heterogeneity but cannot fully attribute it to specific physiologic determinants.
Generalisability and population context
Applicability is strongest to healthy adults with relatively limited external vitamin D inputs and without major metabolic disorders or interacting medications. In that context, the results provide a clear marker-level statement: a single 100,000 IU oral dose can raise serum calcidiol from a mid-20s ng/mL baseline to low-40s ng/mL mean peak, with notable inter-individual variability. For physiology-first site architecture, this supports a “system-level handling” lens: the body’s circulating status marker responds promptly but does not remain indefinitely elevated without repeat input.
Extrapolation becomes less valid as population context diverges from the trial constraints. Individuals with kidney or liver disease were excluded, yet those conditions can alter metabolism and clearance. Granulomatous conditions were excluded because they can alter vitamin D-related pathways and safety context. Medications affecting metabolism were excluded. Therefore, applying the same kinetic expectations to those groups would be speculative. Similarly, populations with high sun exposure or high dietary vitamin D inputs may show different baseline dynamics and different apparent persistence after bolus exposure.
The study itself flags context indirectly through its selection and exclusions: the very need to exclude certain conditions and medications implies that kinetics are not uniform across physiologic states. The control group’s minimal change suggests the study period did not include strong background movement in calcidiol for this cohort, but in different seasonal contexts or latitudes, background drift could be larger. The transferability boundary is therefore defined not only by health status but also by environmental input patterns and baseline variability conditions.
Mechanistic inference boundary
This study provides an intervention-to-marker trajectory: dose in, serum calcidiol pattern out. That is not equivalent to a mechanistic map. The observed rise and decay can be consistent with many internal process combinations, including differences in absorption, initial distribution into tissues, sequestration in depots, conversion rates to calcidiol, binding dynamics in circulation, and elimination. Because the study does not measure these intermediate steps, it cannot claim which mechanisms explain the time course, nor can it claim that the bolus improves or impairs specific physiological functions.
What cannot be concluded includes claims about endocrine versus paracrine versus intracrine signalling integration. The study does not measure tissue-level activation of vitamin D-responsive genes, local production of active hormone, or receptor engagement. It also cannot establish that maintaining serum calcidiol above baseline is necessary or sufficient for any downstream outcome. The dosing-interval statement is therefore a marker-management inference, not a signalling or outcome inference.
The separation of capacity, signalling, and correlation is essential here. Serum calcidiol concentration reflects a circulating pool and is often treated as a capacity-like indicator for vitamin D availability at the system level, but local tissue signalling can be regulated by factors not measured here. Therefore, even a substantial rise in serum calcidiol does not demonstrate proportional change in tissue signalling outcomes, and failure to reach a threshold does not, by itself, demonstrate functional deficiency. The study supports statements about biomarker kinetics following a bolus; it does not support statements about tissue-specific signalling efficacy or clinical endpoint effects.
Interpretation within vitamin D physiology
Within a physiology-first framing, this trial is most defensibly interpreted as evidence about how a discrete cholecalciferol exposure is handled at the system level as reflected by the canonical status metabolite in blood. The prompt rise indicates that a single oral exposure can be translated into increased circulating calcidiol, while the four-month follow-up implies that this effect has a time-limited persistence that trends back toward baseline without repeated input. The heterogeneity result indicates that individuals differ materially in their marker response even under controlled selection conditions, reinforcing that serum concentration is the product of multiple internal steps rather than a simple “dose equals level” relationship.
For relevant physiology background, see Vitamin D in the Body.
Interpretation
Supported interpretation is limited to the measured marker domain: in this healthy adult cohort with constrained sun and milk intake and specific exclusions, a single 100,000 IU oral dose of cholecalciferol increased mean serum calcidiol from 27.1 ± 7.7 ng/mL to a mean maximum of 42.0 ± 9.1 ng/mL, with a highest observed value of 64.2 ng/mL and with 7% failing to reach 32.1 ng/mL at any measured time point. The control group’s non-significant change over the same period supports attribution of the rise to the bolus rather than to seasonal drift in this context.
Boundary restatement: the study does not measure tissue-specific distribution, storage in defined depots, binding protein fractions, active hormone dynamics, receptor activation, or clinical outcomes. Therefore, it cannot support claims about organ-level vitamin D exposure, intracrine/paracrine signalling integration, or disease-relevant endpoint changes. Any interpretation that maps the calcidiol trajectory directly onto functional physiology would require additional evidence not provided here.
Measured versus contextual separation: what is measured is the serum calcidiol trajectory over four months after a single bolus and the presence of inter-individual variability in peak and threshold attainment. Contextual framing (not new claims) is that bolus dosing convenience motivates interest in such kinetics, and the authors infer that dosing intervals longer than two months may allow serum calcidiol to return toward baseline. This inference remains a marker-management conclusion derived from the time course, not a claim about optimal physiology or clinical benefit.
Primary source and publication details
Ilahi M, Armas LAG, Heaney RP
Pharmacokinetics of a single, large dose of cholecalciferol
Am J Clin Nutr. 2008.
DOI: 10.1093/ajcn/87.3.688
https://pubmed.ncbi.nlm.nih.gov/18326608/
Related reading
Can the supplementation of vitamin D, sun exposure, and isolation during the COVID-19 pandemic affect the seasonal concentration of 25(OH)D and selected blood parameters among young soccer players in a one-year training season?
Forty elite young soccer players (age: 17.2 ± 1.16 years, body mass: 70.2 ± 5.84, and body height: 179.1 ± 4.26 cm) participated in the research.
Original paper ↗Read more →Changes of 25(OH)D Concentration, Bone Resorption Markers and Physical Performance as an Effect of Sun Exposure, Supplementation of Vitamin D and Lockdown among Young Soccer Players during a One-Year Training Season
The main purpose of this research was to demonstrate the changes in 25(OH)D concentration, bone resorption markers, and physical fitness along the one-year training season in young soccer players.
Original paper ↗Read more →Influence of Sunlight and Oral D3 Supplementation on Serum 25(OH)D Concentration and Exercise Performance in Elite Soccer Players
The aim of this study was to evaluate the influence of natural sun exposure and six weeks of a high dose of vitamin D supplementation on vitamin D, testosterone and cortisol serum concentrations as well as speed, power and VO2max in professional soccer players.
Original paper ↗Read more →Positive Association between Blood 25-Hydroxyvitamin D Levels and Pterygium after Control for Sunlight Exposure
A total of 19,178 participants aged ≥ 30 years were evaluated for blood 25-hydroxyvitamin D levels and performed ophthalmic slit lamp examinations.
Original paper ↗Read more →Real-life use of vitamin D3-fortified bread and milk during a winter season: the effects of CYP2R1 and GC genes on 25-hydroxyvitamin D concentrations in Danish families, the VitmaD study
Participants were allocated to either vitamin D3-fortified bread and milk or non-fortified bread and milk during winter.
Original paper ↗Read more →Sunlight exposed body surface area is associated with serum 25-hydroxyvitamin D (25(OH)D) level in pregnant Minangkabau women, Indonesia
This study was aimed to elucidate the association of sunlight exposed body surface area with serum 25(OH)D in pregnant Minangkabau women of Indonesia.
Original paper ↗Read more →Relationship between Sleep Duration, Sun Exposure, and Serum 25-Hydroxyvitamin D Status: A Cross-sectional Study
Normal-range sleep duration is an important factor for general health and metabolism, and insufficient or excessive sleep is associated with chronic metabolic disease.
Original paper ↗Read more →Study Summary: Pharmacokinetics of a single, large dose of cholecalciferol
Pharmacokinetics of a Single Large Dose of Cholecalciferol: Study Summary.
Read more →Association between 25(OH)D Level, Ultraviolet Exposure, Geographical Location, and Inflammatory Bowel Disease Activity: A Systematic Review and Meta-Analysis
Studies that compared 25(OH)D levels between IBD patients and controls were selected for inclusion in the meta-analysis.
Original paper ↗Read more →Do Serum 25-Hydroxyvitamin D Concentrations Affect Body Composition, Physical Fitness, Bone Strength and Bone Biomarkers in Female Children and Adolescent Football Players? A One-Season Study
The aim was to compare changes in body composition, physical fitness, and bone biomarkers in female children and adolescent football players with different Vitamin D levels.
Original paper ↗Read more →Effects of narrowband ultraviolet B exposure on serum 25-hydroxyvitamin D concentrations: A pilot study
Thus, the purpose of this study was to investigate the effect of NBUVB-LED exposure on serum 25(OH)D concentrations.
Original paper ↗Read more →Lack of significant seasonal association between serum 25(OH)D concentration, muscle mass and strength in postmenopausal women from the D-FINES longitudinal study
The aim of the present study was to assess the seasonal relationship between serum 25(OH)D concentration, lean mass and muscle strength.
Original paper ↗Read more →Low dose ultraviolet B irradiation at 308 nm with light-emitting diode device effectively increases serum levels of 25(OH)D
This animal study aimed to elucidate the relationship of low-dose, narrow-band UVB at 308 nm with vitamin D synthesis.
Original paper ↗Read more →Oral and Topical Vitamin D, Sunshine, and UVB Phototherapy Safely Control Psoriasis in Patients with Normal Pretreatment Serum 25-Hydroxyvitamin D Concentrations: A Literature Review and Discussion of Health Implications
Vitamin D, sunshine and UVB phototherapy were first reported in the early 1900s to control psoriasis, cure rickets and cure tuberculosis (TB).
Original paper ↗Read more →Seasonal 25-hydroxyvitamin D levels in new childhood-onset SLE: associations with disease activity and peripheral lymphocyte subsets
All participants were divided into a winter-spring group and a summer-autumn group according to sampling seasons.
Original paper ↗Read more →Seasonal Variation in 25(OH)D at Aberdeen (57°N) and Bone Health Indicators: Could Holidays in the Sun and Cod Liver Oil Supplements Alleviate Deficiency?
The aim of this longitudinal study, was to assess predictors of seasonal variation of 25-hydroxy-vitamin D (25(OH)D) (including use of supplements and holidays in sunny destinations) at a northerly latitude in the UK (57°N) in relation to bone health indicators.
Original paper ↗Read more →Seasonal variation of 25-Hydroxyvitamin D and indices of carbohydrate and lipid metabolism in postmenopausal women
Therefore, the purpose of this study was to evaluate the level of carbohydrate and lipid metabolism indices in relation to seasonal changes in 25-hydroxyvitamin D (25(OH)D) concentration in postmenopausal women.
Original paper ↗Read more →Seasonal variation of idiopathic benign paroxysmal positional vertigo correlates with serum 25-hydroxyvitamin D levels: a six-year registry study in Shanghai, China
Seasonal variation of benign paroxysmal positional vertigo (BPPV) occurrence has been reported in recent years.
Original paper ↗Read more →Serum 25-Hydroxyvitamin D Concentrations and Season-Specific Correlates in Japanese Adults
We investigated the association between lifestyle and serum vitamin D concentration by season in Japanese workers.
Original paper ↗Read more →Towards harmonization of directly measured free 25-hydroxyvitamin D using an enzyme-linked immunosorbent assay
The availability of a new enzyme-linked immunosorbent assay (ELISA) for the determination of free 25(OH)D provides a method for direct measurement of the low levels of non-protein bound 25(OH)D.
Original paper ↗Read more →Variations in 25-Hydroxyvitamin D in Countries from the Middle East and Europe: The Roles of UVB Exposure and Diet
Serum 25-hydroxyvitamin D (25(OH)D) has been largely associated with latitude and sunshine exposure across several regions.
Original paper ↗Read more →Original sources
https://pubmed.ncbi.nlm.nih.gov/18326608/
https://pubmed.ncbi.nlm.nih.gov/18326608/.
Publication details
https://pubmed.ncbi.nlm.nih.gov/18326608/